Treatment Advances and Evolving Standard of Care in Atopic Dermatitis - Episode 10
JAK Inhibitors in Atopic Dermatitis
A panel of dermatologists discuss the evolution of JAK inhibitors for atopic dermatitis and how they fit into current treatment paradigms.
Video content above is prompted by the following:
- A number of JAK inhibitors, both oral (abrocitinib, upadacitnib) and topical (ruxolitinib cream), are FDA approved for atopic dermatitis.
- How have JAK inhibitors evolved over the years?
- How have differences between JAK inhibitors led to differences in their safety and efficacy profiles?
